CONCERT PHARMACEUTICALS INC's ticker is CNCE and the CUSIP is 206022105. A total of 86 filers reported holding CONCERT PHARMACEUTICALS INC in Q4 2022. The put-call ratio across all filers is 0.25 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2022 | $6,355,649 | -12.8% | 1,088,296 | 0.0% | 0.13% | -17.3% |
| Q3 2022 | $7,292,000 | -47.6% | 1,088,296 | -67.1% | 0.16% | -58.0% |
| Q2 2022 | $13,923,000 | +36.2% | 3,307,203 | +9.0% | 0.37% | +66.4% |
| Q1 2022 | $10,223,000 | +7.0% | 3,033,603 | 0.0% | 0.22% | +32.7% |
| Q4 2021 | $9,556,000 | -3.7% | 3,033,603 | 0.0% | 0.17% | +22.6% |
| Q3 2021 | $9,920,000 | -22.5% | 3,033,603 | 0.0% | 0.14% | -33.2% |
| Q2 2021 | $12,802,000 | -15.4% | 3,033,603 | 0.0% | 0.20% | -10.1% |
| Q1 2021 | $15,138,000 | -34.3% | 3,033,603 | +66.4% | 0.23% | -29.2% |
| Q4 2020 | $23,049,000 | +26.3% | 1,823,520 | -1.9% | 0.32% | -3.6% |
| Q3 2020 | $18,250,000 | -1.3% | 1,858,474 | 0.0% | 0.33% | -7.2% |
| Q2 2020 | $18,492,000 | +12.6% | 1,858,474 | 0.0% | 0.36% | -30.6% |
| Q1 2020 | $16,429,000 | +65.1% | 1,858,474 | +178.0% | 0.52% | -48.2% |
| Q2 2015 | $9,953,000 | -0.4% | 668,406 | +1.3% | 1.00% | +0.8% |
| Q1 2015 | $9,996,000 | – | 660,000 | – | 0.99% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Kynam Capital Management, LP | 4,420,349 | $25,814,838 | 3.96% |
| Parkman Healthcare Partners LLC | 1,203,484 | $7,028,347 | 1.87% |
| SPHERA FUNDS MANAGEMENT LTD. | 1,002,783 | $5,856,253 | 1.26% |
| TANG CAPITAL MANAGEMENT LLC | 1,150,000 | $6,716,000 | 0.98% |
| BVF INC/IL | 3,629,000 | $21,193,360 | 0.89% |
| Nantahala Capital Management | 1,732,388 | $10,117,146 | 0.66% |
| AWM Investment Company, Inc. | 666,661 | $3,893,300 | 0.56% |
| INGALLS & SNYDER LLC | 1,295,833 | $7,568 | 0.41% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 200,800 | $1,172,672 | 0.36% |
| Kensington Investment Counsel, LLC | 58,599 | $342,218 | 0.27% |